United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - methotrexate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - methotrexate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - methotrexate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - methotrexate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - methotrexate - oral tablet - 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.82 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; hydrochloric acid - malignant pleural mesothelioma -pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer - pemetrexed-aft in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed-aft as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604.12 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid; mannitol - malignant pleural mesothelioma -pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer - pemetrexed-aft in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed-aft as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - pemetrexed disodium hemipentahydrate 110.29mg equivalent to pemetrexed 100mg - powder for infusion - 100 mg - active: pemetrexed disodium hemipentahydrate 110.29mg equivalent to pemetrexed 100mg excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma pemetrexed accord, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - pemetrexed disodium hemipentahydrate 1102.9mg equivalent to pemetrexed 1000 mg - powder for infusion - 1000 mg - active: pemetrexed disodium hemipentahydrate 1102.9mg equivalent to pemetrexed 1000 mg excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma pemetrexed accord, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - pemetrexed disodium hemipentahydrate 551.45mg equivalent to pemetrexed 500 mg - powder for infusion - 500 mg - active: pemetrexed disodium hemipentahydrate 551.45mg equivalent to pemetrexed 500 mg excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma pemetrexed accord, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.